Cancer’s Vulnerability is Our Strength

Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.

Learn More

Scientific Approach

Oncogenic transformations lead to DNA breaks that require repair for cancer cells to survive. This makes cancer cells vulnerable to targeted programs that disrupt DNA damage response and repair. Cyteir drug treatments have the potential to exploit this vulnerability by inducing synthetic lethality in tumor cells while sparing normal cells.

Learn More


Novel, drug candidates targeting key cancer vulnerabilities



Enrollment is open in our Phase 1/2 trial for solid tumors and hematologic malignancies



At Cyteir, patients come first, science is key and collaboration is valued. Come join us!


Cyteir’s Culture

With a pioneering spirit, putting patients first, we advance science passionately and collaboratively, in a fun learning environment. We value open, honest and transparent communication. We work diligently with respect for each other with a sense of urgency, integrity, accountability and purpose.​

Learn More

“The development and approval of PARP inhibitors have paved the way for additional, novel DNA repair and synthetic lethality-based therapies to address unmet needs in cancer treatment.”

Markus Renschler, MD
President and Chief Executive Officer